Researchers at Weill Cornell Medical College in Qatar have made a major step towards understanding why certain cancers often recur after they have been treated with conventional therapies. Read more
David Lyden’s blood test to isolate cancer released exosomes was one of six projects selected as winners of the inaugural Daedalus Fund for Innovation. Read more
A feature in Weill Cornell Medicine highlights some of the work being done by John Leonard, Leandro Cerchietti, Ari Melnick and others at the Meyer Cancer Center to tailor treatments to individual patients. Read more
Race and ethnicity dramatically influence patients' end-of-life preferences, which affect the likelihood they will complete a do-not-resuscitate order. Read more
Work by Andrea Shoner and his team has demonstrated that organ tissue derived from human prostate cancer tumors can be grown in the laboratory, giving researchers a new tool to test cancer drugs and personalize cancer treatment. Read more
“Once-in-a-generation” researcher John Blenis joins the Meyer Cancer Center team as Anna-Maria and Stephen Kellen Professor of Cancer Research. Read more
A research team led by Selina Chen-Kiang has revealed key insights into why late resistance to breakthrough drug ibrutinib occurs in many mantle cell lymphoma patients, and has shown preclinical success with two new treatment strategies. Read more
Researchers at Weill Cornell Medical College have discovered what they believe may be the first effective drug therapy to prevent tongue cancer, one of the world's most common cancers. Read more
Meyer Cancer Center director Lewis Cantley has collaborated with fellow Breakthrough Prize award winners to establish a new annual life sciences award for postdocs. Read more
A $75 million gift from Sandra and Edward Meyer ’48 and the Sandra and Edward Meyer Foundation will enhance the medical college’s distinguished cancer research and care programs. Read more
Feature in Science highlights Selina Chen-Kiang’s dogged determination in her quest to resurrect the drug palbociclib for its potential in treating blood cancers. Read more